Non-Covalent BTK Inhibitors-The New BTKids on the Block for B-Cell Malignancies

The B-cell receptor signalling pathway plays a critical role in development of B-cell malignancies, and the central role of Bruton's tyrosine kinase (BTK) activation in this pathway provides compelling rationale for BTK inhibition as a therapeutic strategy for these conditions. Covalent BTK inhibitors (BTKi) have transformed the treatment landscape of B-cell malignancies, but adverse events and treatment resistance have emerged as therapeutic challenges, with the majority of patients eventually discontinuing treatment due to toxicity or disease progression. Non-covalent BTKi have alternative mechanisms of binding to BTK than covalent BTKi, and therefore offer a therapeutic alternative for patients with B-cell malignancies, including those who have been intolerant to, or experienced disease progression during treatment with a covalent BTKi. Here, we summarise the clinical data, adverse events and mechanisms of resistance observed with covalent BTKi and describe the emerging data for non-covalent BTKi as a novel treatment for B-cell malignancies.

Automated summary

The B-cell receptor signalling pathway is crucial in the development of B-cell malignancies, with Bruton's tyrosine kinase (BTK) activation as a central element. While covalent BTK inhibitors have revolutionized treatment, issues such as adverse events and resistance have led to the exploration of non-covalent BTK inhibitors as an alternative therapeutic option. These non-covalent BTK inhibitors offer promise for patients intolerant to or experiencing disease progression with traditional covalent BTK inhibitors.